Last update Jan. 9, 2023
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Cetrorelix Acetate in other languages or writings:
Cetrorelix Acetate belongs to this group or family:
Main tradenames from several countries containing Cetrorelix Acetate in its composition:
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Cetrorelix is a synthetic decapeptide antagonist of gonadorelin (gonadotropin-releasing hormone) that is used to prevent luteinizing hormone surges and premature ovulation in women undergoing ovarian stimulation treatment for assisted reproduction in cases of infertility. It is also used in endometriosis and uterine fibroids. Subcutaneous or intramuscular administration.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (high percentage of protein binding, high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
Its low oral bioavailability makes it difficult for it to pass to the infant’s plasma via ingested breast milk as, due to its protein nature, it degrades in the gastrointestinal tract and is not absorbed.
Similar products of shorter half-life may be preferable.
See below the information of this related product: